Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

被引：0
作者：
Philip Conaghan
Stanley Cohen
Gerd Burmester
Eduardo Mysler
Peter Nash
Yoshiya Tanaka
William Rigby
Jayeshkumar Patel
Tim Shaw
Keith A. Betts
Pankaj Patel
Jianzhong Liu
Rochelle Sun
Roy Fleischmann
机构：
[1] Leeds Biomedical Research Centre–University of Leeds,Leeds Institute of Rheumatic and Musculoskeletal Medicine, National Institute for Health Research
[2] Metroplex Clinical Research Center,The First Department of Internal Medicine
[3] Charité-Universitätsmedizin Berlin,Metroplex Clinical Research Center
[4] Organización Médica de Investigación,undefined
[5] Griffith University,undefined
[6] University of Occupational and Environmental Health Japan,undefined
[7] Dartmouth-Hitchcock Medical Center,undefined
[8] AbbVie,undefined
[9] Inc,undefined
[10] AbbVie Ltd,undefined
[11] Analysis Group,undefined
[12] Inc,undefined
[13] Analysis Group,undefined
[14] Inc,undefined
[15] University of Texas Southwestern Medical Center,undefined
来源：
Rheumatology and Therapy | 2022年 / 9卷
关键词：
Benefit–risk assessment; Number needed to treat; Number needed to harm; Efficacy; Safety; Rheumatoid arthritis; Upadacitinib; Janus kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 206
页数：15
相关论文
共 100 条
[1]  
Radner H(2015)Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients Arthritis Res Ther 17 203-1372
[2]  
Alasti F(2018)Diagnosis and management of rheumatoid arthritis: a review JAMA 320 1360-511
[3]  
Smolen JS(2012)Disability in rheumatoid arthritis in the era of biological treatments Ann Rheum Dis 71 213-695
[4]  
Aletaha D(2015)Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism Best Pract Res Clin Rheumatol 29 495-772
[5]  
Aletaha D(2016)A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective Rheumatol Int 36 685-8
[6]  
Smolen JS(2009)Contemporary treatment principles for early rheumatoid arthritis: a consensus statement Rheumatology (Oxford) 48 765-738
[7]  
Krishnan E(2002)Evidence supporting the benefit of early intervention in rheumatoid arthritis J Rheumatol Suppl 66 3-2372
[8]  
Lingala B(2019)Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis Clin Rheumatol 38 727-267
[9]  
Bruce B(2020)Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis Adv Ther 37 2356-32
[10]  
Fries JF(2019)IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review Mod Rheumatol 29 258-184
12345678910